Clinical Roundup Tecentriq + tiragolumab does not improve OS, updated phase III data finds December 06, 2024Vol.50 No.45
Drugs & Targets FDA approves inavolisib + palbociclib + fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer October 11, 2024Vol.50 No.38
Clinical Roundup Tiragolumab + atezolizumab for metastatic nSq NSCLC did not meet primary endpoints in phase II/III trial July 12, 2024Vol.50 No.28
Clinical Roundup Columvi combination extends OS in transplant-ineligible R/R DLBCL in phase III trial June 21, 2024Vol.50 No.25
Clinical Roundup Inavolisib combination demonstrates 57% PFS in breast cancer indication January 05, 2024Vol.50 No.01
Clinical Roundup Kadcyla demonstrates OS benefit in breast cancer indication January 05, 2024Vol.50 No.01
Clinical Roundup Phase III ALINA study: Alecensa reduces risk of disease recurrence/death in NSCLC October 27, 2023Vol.49 No.40
Clinical Roundup Phase III data demonstrate Alecensa reduces disease recurrence in the early setting for ALK-positive NSCLC September 08, 2023Vol.49 No.33
